Insilico Medicine
3deals in 2026
—raised
| Date | Type | Amount | Upfront | Investors / partner | Notes | Source |
|---|---|---|---|---|---|---|
| 2 Jul 2026 | Partnership (discovery) | $600.0M | $60.0M | Takeda | ~$60M = initiation fees + near-term payments; total up to ~$600M | Source |
| 22 Jun 2026 | Partnership (R&D) | $2.50B | $18.0M | SK Biopharmaceuticals | Upfront figure = up to $18M upfront + near-term milestones; total >$2.5B | Source |
| 29 Mar 2026 | Partnership (licensing + discovery) | $2.75B | $115.0M | Eli Lilly | Total up to ~$2.75B incl. milestones; plus royalties | Source |